Together, our preclinical investigations provide proof-of-concept evidence that selective PHD inhibition is highly anti-leukemogenic, setting the stage for a promising therapeutic approach to AML treatment, without any toxic effects on normal hematopoiesis. Here, PDC is linked to acute myeloid leukemia.